Johnson & Johnson Profits Edge Up

JNJThird-quarter earnings for Johnson & Johnson (NYSE: JNJ – $90.10) edged up slightly as the healthcare products giant was again supported by new prescription drugs as it seeks to replace older blockbusters that have lost patent protection. Excluding charges related to last year’s acquisition of trauma-device maker Synthes, litigation-related impacts and other items, New Brunswick, N.J-based J&J reported adjusted earnings of $1.36, up from $1.25 a year ago. Revenue increased 3.1% to $17.6 billion. Analysts recently expected per-share earnings of $ 1.32 and revenue of $17.44 billion. For the full year, J&J raised its per-share earnings estimate to $5.44 to $5.49, from its previous estimate of $5.40 to $5.45. This top-quality blue chip is a good option for conservative income-oriented investors. The shares yield 2.9%, at current quotations.

JNJ

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: